NCT06134622View on ClinicalTrials.gov

Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)

PHASE3CompletedINTERVENTIONAL
Enrollment

832

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

September 25, 2024

Study Completion Date

December 30, 2024

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Intravenous thrombolysis plus tirofiban

Patients randomized to the Tirofiban group will receive continuous intravenous infusion of tirofiban for 24 hours: initial infusion of 0.4 μg/kg/min for 30 minutes followed by a continuous infusion of 0.1 μg/kg/min for up to 23.5 hours. The tirofiban placebo will be infused in a similar fashion.

DRUG

Intravenous thrombolysis plus placebo

placebo (saline)

Trial Locations (1)

230001

The First Affiliated Hospital of University of Science and Technology of China, Hefei

All Listed Sponsors
lead

The First Affiliated Hospital of University of Science and Technology of China

OTHER

NCT06134622 - Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT) | Biotech Hunter | Biotech Hunter